Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;9(3):669-675.
doi: 10.1007/s40121-020-00316-3. Epub 2020 Jul 8.

Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease

Danielle E Anderson #  1 , Velraj Sivalingam #  2 , Adrian Eng Zheng Kang #  2 , Abhishek Ananthanarayanan  3 , Harsha Arumugam  3 , Timothy M Jenkins  4 , Yacine Hadjiat  3 , Maren Eggers  5
Affiliations

Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease

Danielle E Anderson et al. Infect Dis Ther. 2020 Sep.

Abstract

Introduction: As of 22 June 2020, Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV)-2 has infected more than 8.95 million people worldwide, causing > 468,000 deaths. The virus is transmitted through respiratory droplets and physical contact from contaminated surfaces to the mucosa. Hand hygiene and oral decontamination among other measures are key to preventing the spread of the virus. We report the in vitro virucidal activity of topical and oral povidone-iodine (PVP-I) products against SARS-CoV-2.

Methods: Suspension assays were used to assess the virucidal activity of PVP-I against SARS-CoV-2. Products were tested at a contact time of 30 s for virucidal activity. Viral titres were calculated using the Spearman-Kärber method and reported as median tissue culture infectious dose (TCID50)/mL.

Results: All four products [antiseptic solution (PVP-I 10%), skin cleanser (PVP-I 7.5%), gargle and mouth wash (PVP-I 1%) and throat spray (PVP-I 0.45%)] achieved ≥ 99.99% virucidal activity against SARS-CoV-2, corresponding to ≥ 4 log10 reduction of virus titre, within 30 s of contact.

Conclusion: This study provides evidence of rapid and effective virucidal activity of PVP-I against SARS-CoV-2. PVP-I-based products are widely available for medical and personal use for hand hygiene and oral decontamination, and could be readily integrated into coronavirus disease, COVID-19, infection control measures in hospital and community settings.

Keywords: Anti-infective agents; COVID-19; PVP-I; Povidone-iodine; SARS-CoV-2; Upper respiratory tract infections; Viruses.

PubMed Disclaimer

References

    1. World Health Organisation. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020: World Health Organisation. 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re.... Accessed 11 May 2020.
    1. Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int J Infect Dis. 2020;92:214–217. doi: 10.1016/j.ijid.2020.01.050. - DOI - PMC - PubMed
    1. Johns Hopkins University and Medicine. Coronavirus Resource Center: John Hopkins University. 2020. https://coronavirus.jhu.edu/map.html. Accessed 22 June 2020.
    1. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018;100:163–188. doi: 10.1016/bs.aivir.2018.01.001. - DOI - PMC - PubMed
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed